Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes

A. Bergamini, C. F. Perno, J. Balzarini, M. Capozzi, L. Marinelli, G. Milanese, C. D. Pesce, R. Calio, G. Rocchi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Adriamycin (ADR) is an anticancer drug commonly used in the treatment of HIV-related cancers. Due to its effect on DNA metabolism, ADR might be able to modulate HIV replication in monocyte-macrophages (M/M), resting cells potentially less sensitive to the toxic effect of this drug. Thus, we assessed the efficacy of ADR against HIV replication in both lymphocytes and M/M. We further investigated the mechanism(s) of action of ADR and its potential synergistic activity with zidovudine (AZT) or alpha-interferon (IFNα). ADR consistently inhibited viral replication in M/M: 50% viral inhibition was obtained with 0.005 μg/ml ADR, while >90% viral inhibition was obtained with 0.05 μg/ml ADR. No cell toxicity was seen in M/M at concentrations up to 0.5 μg/ml. No anti-HIV activity was shown by ADR in lymphocytes at concentrations up to 0.05 μg/ml, that is also the toxic dose 50% (TCID50 for these cells). ADR neither inactivates HIV virions nor affects HIV binding with CD4 receptors. No inhibition of HIV reverse transcriptase by ADR was found at concentrations at least 2,000-fold greater than the 50% HIV inhibitory concentration in M/M. Molecular analysis by polymerase chain reaction (PCR) suggests that ADR substantially affects virus DNA production at concentrations that inhibit viral replication. Finally, late stages of HIV replication were not affected by ADR. At least additive effects of the association ADR + AZT and ADR + IFNα were obtained against de novo HIV infection of M/M. In conclusion, ADR is able to inhibit HIV in M/M at concentrations toxic for replicating cells such as lymphocytes, but still in the range of those usually achieved in cancer patients: its mechanism of antiviral activity is probably related to the block of HIV-DNA functionality. Thus, ADR and its derivatives may deserve further research to better define their antiviral activity alone or in association with AZT or other anti-HIV drugs.

Original languageEnglish
Pages (from-to)1239-1247
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume8
Issue number7
Publication statusPublished - 1992

Fingerprint

Doxorubicin
Macrophages
HIV
Lymphocytes
Monocytes
Poisons
Antiviral Agents
HIV Reverse Transcriptase
Anti-HIV Agents
CD4 Antigens
DNA Viruses
Second Primary Neoplasms
Zidovudine
Interferon-alpha
Pharmaceutical Preparations
Virion
Interferons
Inhibitory Concentration 50
HIV Infections

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Bergamini, A., Perno, C. F., Balzarini, J., Capozzi, M., Marinelli, L., Milanese, G., ... Rocchi, G. (1992). Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes. AIDS Research and Human Retroviruses, 8(7), 1239-1247.

Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes. / Bergamini, A.; Perno, C. F.; Balzarini, J.; Capozzi, M.; Marinelli, L.; Milanese, G.; Pesce, C. D.; Calio, R.; Rocchi, G.

In: AIDS Research and Human Retroviruses, Vol. 8, No. 7, 1992, p. 1239-1247.

Research output: Contribution to journalArticle

Bergamini, A, Perno, CF, Balzarini, J, Capozzi, M, Marinelli, L, Milanese, G, Pesce, CD, Calio, R & Rocchi, G 1992, 'Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes', AIDS Research and Human Retroviruses, vol. 8, no. 7, pp. 1239-1247.
Bergamini A, Perno CF, Balzarini J, Capozzi M, Marinelli L, Milanese G et al. Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes. AIDS Research and Human Retroviruses. 1992;8(7):1239-1247.
Bergamini, A. ; Perno, C. F. ; Balzarini, J. ; Capozzi, M. ; Marinelli, L. ; Milanese, G. ; Pesce, C. D. ; Calio, R. ; Rocchi, G. / Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes. In: AIDS Research and Human Retroviruses. 1992 ; Vol. 8, No. 7. pp. 1239-1247.
@article{a1c6b024d63747008dff3e24f94aff37,
title = "Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes",
abstract = "Adriamycin (ADR) is an anticancer drug commonly used in the treatment of HIV-related cancers. Due to its effect on DNA metabolism, ADR might be able to modulate HIV replication in monocyte-macrophages (M/M), resting cells potentially less sensitive to the toxic effect of this drug. Thus, we assessed the efficacy of ADR against HIV replication in both lymphocytes and M/M. We further investigated the mechanism(s) of action of ADR and its potential synergistic activity with zidovudine (AZT) or alpha-interferon (IFNα). ADR consistently inhibited viral replication in M/M: 50{\%} viral inhibition was obtained with 0.005 μg/ml ADR, while >90{\%} viral inhibition was obtained with 0.05 μg/ml ADR. No cell toxicity was seen in M/M at concentrations up to 0.5 μg/ml. No anti-HIV activity was shown by ADR in lymphocytes at concentrations up to 0.05 μg/ml, that is also the toxic dose 50{\%} (TCID50 for these cells). ADR neither inactivates HIV virions nor affects HIV binding with CD4 receptors. No inhibition of HIV reverse transcriptase by ADR was found at concentrations at least 2,000-fold greater than the 50{\%} HIV inhibitory concentration in M/M. Molecular analysis by polymerase chain reaction (PCR) suggests that ADR substantially affects virus DNA production at concentrations that inhibit viral replication. Finally, late stages of HIV replication were not affected by ADR. At least additive effects of the association ADR + AZT and ADR + IFNα were obtained against de novo HIV infection of M/M. In conclusion, ADR is able to inhibit HIV in M/M at concentrations toxic for replicating cells such as lymphocytes, but still in the range of those usually achieved in cancer patients: its mechanism of antiviral activity is probably related to the block of HIV-DNA functionality. Thus, ADR and its derivatives may deserve further research to better define their antiviral activity alone or in association with AZT or other anti-HIV drugs.",
author = "A. Bergamini and Perno, {C. F.} and J. Balzarini and M. Capozzi and L. Marinelli and G. Milanese and Pesce, {C. D.} and R. Calio and G. Rocchi",
year = "1992",
language = "English",
volume = "8",
pages = "1239--1247",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes

AU - Bergamini, A.

AU - Perno, C. F.

AU - Balzarini, J.

AU - Capozzi, M.

AU - Marinelli, L.

AU - Milanese, G.

AU - Pesce, C. D.

AU - Calio, R.

AU - Rocchi, G.

PY - 1992

Y1 - 1992

N2 - Adriamycin (ADR) is an anticancer drug commonly used in the treatment of HIV-related cancers. Due to its effect on DNA metabolism, ADR might be able to modulate HIV replication in monocyte-macrophages (M/M), resting cells potentially less sensitive to the toxic effect of this drug. Thus, we assessed the efficacy of ADR against HIV replication in both lymphocytes and M/M. We further investigated the mechanism(s) of action of ADR and its potential synergistic activity with zidovudine (AZT) or alpha-interferon (IFNα). ADR consistently inhibited viral replication in M/M: 50% viral inhibition was obtained with 0.005 μg/ml ADR, while >90% viral inhibition was obtained with 0.05 μg/ml ADR. No cell toxicity was seen in M/M at concentrations up to 0.5 μg/ml. No anti-HIV activity was shown by ADR in lymphocytes at concentrations up to 0.05 μg/ml, that is also the toxic dose 50% (TCID50 for these cells). ADR neither inactivates HIV virions nor affects HIV binding with CD4 receptors. No inhibition of HIV reverse transcriptase by ADR was found at concentrations at least 2,000-fold greater than the 50% HIV inhibitory concentration in M/M. Molecular analysis by polymerase chain reaction (PCR) suggests that ADR substantially affects virus DNA production at concentrations that inhibit viral replication. Finally, late stages of HIV replication were not affected by ADR. At least additive effects of the association ADR + AZT and ADR + IFNα were obtained against de novo HIV infection of M/M. In conclusion, ADR is able to inhibit HIV in M/M at concentrations toxic for replicating cells such as lymphocytes, but still in the range of those usually achieved in cancer patients: its mechanism of antiviral activity is probably related to the block of HIV-DNA functionality. Thus, ADR and its derivatives may deserve further research to better define their antiviral activity alone or in association with AZT or other anti-HIV drugs.

AB - Adriamycin (ADR) is an anticancer drug commonly used in the treatment of HIV-related cancers. Due to its effect on DNA metabolism, ADR might be able to modulate HIV replication in monocyte-macrophages (M/M), resting cells potentially less sensitive to the toxic effect of this drug. Thus, we assessed the efficacy of ADR against HIV replication in both lymphocytes and M/M. We further investigated the mechanism(s) of action of ADR and its potential synergistic activity with zidovudine (AZT) or alpha-interferon (IFNα). ADR consistently inhibited viral replication in M/M: 50% viral inhibition was obtained with 0.005 μg/ml ADR, while >90% viral inhibition was obtained with 0.05 μg/ml ADR. No cell toxicity was seen in M/M at concentrations up to 0.5 μg/ml. No anti-HIV activity was shown by ADR in lymphocytes at concentrations up to 0.05 μg/ml, that is also the toxic dose 50% (TCID50 for these cells). ADR neither inactivates HIV virions nor affects HIV binding with CD4 receptors. No inhibition of HIV reverse transcriptase by ADR was found at concentrations at least 2,000-fold greater than the 50% HIV inhibitory concentration in M/M. Molecular analysis by polymerase chain reaction (PCR) suggests that ADR substantially affects virus DNA production at concentrations that inhibit viral replication. Finally, late stages of HIV replication were not affected by ADR. At least additive effects of the association ADR + AZT and ADR + IFNα were obtained against de novo HIV infection of M/M. In conclusion, ADR is able to inhibit HIV in M/M at concentrations toxic for replicating cells such as lymphocytes, but still in the range of those usually achieved in cancer patients: its mechanism of antiviral activity is probably related to the block of HIV-DNA functionality. Thus, ADR and its derivatives may deserve further research to better define their antiviral activity alone or in association with AZT or other anti-HIV drugs.

UR - http://www.scopus.com/inward/record.url?scp=0026767810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026767810&partnerID=8YFLogxK

M3 - Article

C2 - 1381599

AN - SCOPUS:0026767810

VL - 8

SP - 1239

EP - 1247

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 7

ER -